Toxicity test, Dose determination, Pharmacokinetic study,Tumor Biodistribution Assay and Efficacy trial

 GBA D409V knock-in (KI) mouse. Express the mutant D409V GBA protein, developed by the Micahel J. Fox Foundation. https://www.jax.org/strain/019106

These Gba*L444P mice contain the mutation L444P in exon 10 of the GBA gene. This mutation introduces a leucine to proline mutation analogous to a common Gba mutation found in humans with the α-synucleinopathy. https://www.jax.org/strain/024574

Neurotoxic model most used for research in Parkinson's disease as it shows a robust and reproducible phenotype due to repeated administration of the Parkinson-causing MPTP neurotoxin. This phenotype is characterized by mimicking the neurodegeneration of dopaminergic neurons linked to Parkinson's disease.

Partial and calibrated ligation of the portal vein causing hyperdynamic syndrome at 4 days and after a 2 weeks the systemic portal shunting is close to 100%.

This mouse model was generated by inserting loxP sites flanking exons 4-5 of the Ppargc1a (encoding for the co-activator PGC1alpha). The model enables time-restricted and tissue-specific ablation of the Ppargc1a gene.

This mouse model was generated by inserting loxP sites flanking exons 4-5 of the Ppargc1b (encoding for the co-activator PGC1beta). The model enables time-restricted and tissue-specific ablation of the Ppargc1b gene.

Subcutaneous implantation of tumor cells (PC3; Du-145; VCaP; 22Rv; LNCaP; LNCaP AI) for antineoplasic drug efficacy, biodistribution and toxicity assays

Subcutaneous inoculation of colon cancer CT26 cells

Subcutaneous inoculation of melanoma Mel4434 and Mel5555 cancer cells.